Company: ATRA
Filing Date: 2025-04-04
Form Type: 8-K
Source: 0000950170-25-051121
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On March 31, 2025, Atara Biotherapeutics, Inc., (the “ Company”) entered into an Amendment (the “ Amendment”) to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the “ Agreement”) with Pierre Fabre Medicament (“ Pierre Fabre”). Under the terms of the Amendment, as of March 31, 2025, the Company has completed the transfer of all manufacturing responsibility to Pierre Fabre and Pierre Fabre will be, at its cost, responsible for manufacturing and supplying tabelecleucel for development and commercialization worldwide. Pierre Fabre has also agreed to assume the costs related to remediation of the third-party manufacturing facility to address the U. S. Food and Drug Administration’s (the “ FDA”) requests to support resubmission of the BLA for tab-cel.

In exchange for accelerating the transfer of all manufacturing responsibility and assumption of such remediation costs by Pierre Fabre, among other things, the Company agreed to reduce the amount of certain potential future regulatory and commercial milestone payments under the Agreement. The Amendment did not change any of the royalties the Company is eligible to receive under the Agreement. Pursuant to the Amendment, the Company is now entitled to receive an aggregate of up to $550.0 million in additional potential milestone payments upon achieving certain regulatory and commercial milestones relating to tab-cel, including up to $40.0 million in potential regulatory milestones in connection with the approval by the FDA of a BLA for tab-cel under the terms of the Agreement (as amended by the Amendment).

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                         ATARA BIOTHERAPEUTICS, INC.                                
  Date:      April 4, 2025      By:      /s/ AnhCo Thieu Nguyen                                     
                                         AnhCo Thieu Nguyen